Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02878603 · ClinicalTrials.gov registry record · Phase 3
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
NCT02878603 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 104 participants.
The verdict
NCT02878603, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
Study Summary
The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).
Interventions
- OTHER Standard of Care
- BIOLOGICAL Caplacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2016-10-06 |
| Est. Completion | 2020-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02878603
The ClinicalTrials.gov registry entry for NCT02878603 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT02878603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02878603 about?
NCT02878603 is a clinical study titled "Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)". The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).
What is the current status of trial NCT02878603?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2016-10-06. Estimated completion is 2020-10-23.
What interventions are being tested in trial NCT02878603?
The interventions under investigation include: Standard of Care (OTHER), Caplacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02878603?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.